Emgality (Galcanezumab) 120 mg/mL Injection

Emgality® (Galcanezumab) 120 mg/mL Injection

Emgality® is a biological medicinal product containing galcanezumab, a monoclonal antibody indicated for the preventive treatment of migraine. It targets the calcitonin gene-related peptide (CGRP), a key mediator involved in migraine pathophysiology.

Emgality® is administered via subcutaneous injection using a prefilled single-dose pen.

Active Substance

• Galcanezumab (galcanezumab-gnlm) — 120 mg/mL

Indications

Emgality® is indicated for:

• preventive treatment of migraine in adults
• treatment of episodic cluster headache (according to approved indications)

Mode of Action

Galcanezumab is a humanized monoclonal antibody that selectively binds to CGRP and inhibits its activity, thereby reducing the frequency and severity of migraine attacks.

Dosage Form

• Solution for subcutaneous injection
• Prefilled single-dose pen
• Strength: 120 mg/mL
• Single-use only

Key Features

• Targeted migraine prevention therapy
• Long-acting biological medicine
• Convenient administration schedule
• No daily dosing required
• Next-generation CGRP inhibitor

Manufacturer

Eli Lilly and Company

United States